1,148 Shares in Cencora, Inc. (NYSE:COR) Bought by Kera Capital Partners Inc.

Kera Capital Partners Inc. acquired a new stake in shares of Cencora, Inc. (NYSE:COR) in the 4th quarter, Holdings Channel.com reports. The fund acquired 1,148 shares of the company’s stock, valued at approximately $258,000.

Other hedge funds have also recently modified their holdings of the company. Concord Wealth Partners purchased a new position in Cencora during the 3rd quarter valued at about $30,000. Householder Group Estate & Retirement Specialist LLC increased its stake in shares of Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after purchasing an additional 69 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of Cencora during the third quarter valued at approximately $41,000. Fairscale Capital LLC bought a new stake in shares of Cencora in the 2nd quarter worth approximately $54,000. Finally, Modus Advisors LLC purchased a new stake in shares of Cencora in the 4th quarter worth approximately $54,000. Institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 0.5 %

Shares of COR stock opened at $242.11 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $253.27. The stock has a market capitalization of $46.80 billion, a P/E ratio of 32.24, a P/E/G ratio of 1.48 and a beta of 0.49. The firm’s 50 day moving average is $237.52 and its 200 day moving average is $233.93.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.91%. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is presently 29.29%.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 94,696 shares of company stock worth $22,862,734. 15.80% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Leerink Partners lowered their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. UBS Group upped their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Wells Fargo & Company reduced their price objective on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. Mizuho began coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. Finally, Robert W. Baird raised their price target on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $275.60.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.